WO2005012267A1 - アルコキシ-テトラゾール-1-イル-ベンズアルデヒド化合物およびその製造方法 - Google Patents
アルコキシ-テトラゾール-1-イル-ベンズアルデヒド化合物およびその製造方法 Download PDFInfo
- Publication number
- WO2005012267A1 WO2005012267A1 PCT/JP2004/010437 JP2004010437W WO2005012267A1 WO 2005012267 A1 WO2005012267 A1 WO 2005012267A1 JP 2004010437 W JP2004010437 W JP 2004010437W WO 2005012267 A1 WO2005012267 A1 WO 2005012267A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tetrazole
- phenyl
- alkoxy
- formula
- alkyl group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
Definitions
- the present invention relates to a novel alkoxy-tetrazole-1-ylbenzaldehyde compound and a method for producing the same.
- Alkoxy-tetrazole-1-ylbenzaldehyde compounds have been reported for use as pharmaceutical intermediates.
- 2-methoxy-5- (5-methyl-1-tetrazole-11-yl) -benzaldehyde is known to be useful as a key intermediate in pharmaceuticals useful primarily as analgesics or anti-inflammatory agents.
- 2-methoxy-5- (5-trifluoromethyl-tetrazol-1-yl) -benzaldehyde is known to be useful as an important intermediate of drugs that are mainly useful as analgesics.
- W096Z29326 the formylation reaction of aromatic compounds has been studied for a long time, and various methods have been reported.
- Representative examples include (1) a method using dimethylformamide and oxysyndroline (Org. Synth., Coll. Vol., 4th edition, 1963, p. 539), ( 2) A method using dimethylformamide and trifluoromethanesulfonic anhydride (J. Chem. Soc., Chem. Co., Ltd. un.), 1990, p. 1571), (3) A method using hexamethylenetetramin and trifluoroacetic acid (J. Org. Chem., 37th edition, 1972, p. 3972), (4) A method using imidazole and trifluoroacetic anhydride ( Tetrahedron., 36th edition, 1980, p.
- An object of the present invention is to provide a method capable of safely and efficiently producing an alkoxy-tetrazole-1-ylbenzaldehyde compound by formylating an 11- (alkoxy-phenyl) -1H-tetrazole compound. Is to do.
- Other objects and features of the present invention will become apparent from the following description.
- the present inventors have conducted intensive studies to achieve the above object, and as a result, reacted a 1- (alkoxy-phenyl) _1H-tetrazole compound with hexanemethylenetetramine in a sulfonic acid solvent, followed by hydrolysis. As a result, they have found that an alkoxy-tetrazol-1-ylbenzaldehyde compound can be produced safely and efficiently, and have completed the present invention.
- the present invention provides an alkoxy-tetrazol-1-yl rubenzaldehyde compound and a method for producing the same as described below.
- a 1 represents an alkoxyl group
- a 2 represents a hydrogen atom, an alkyl group, or an alkyl group substituted with fluorine.
- sulfonic acid solvent is a mixed solvent of methanesulfonic acid and trifluoromethanesulfonic acid.
- a 1 represents a methoxy group
- a 2 represents a hydrogen atom, a methyl group, an ethyl group or a trifluoromethyl group.
- a 1 represents an alkoxyl group
- a 2 represents a hydrogen atom, an alkyl group, or an alkyl group substituted with fluorine.
- a general formula (4) characterized by reacting a 1- (2-alkoxy-phenyl) -1H-tetrazole hydride compound represented by the following formula with hexamethylenetetramine in a sulfonic acid solvent, followed by hydrolysis:
- a 1 represents an alkoxyl group
- a 2 represents a hydrogen atom, an alkyl group, or an alkyl group substituted with fluorine.
- a general formula (6) characterized by reacting a 1- (3-alkoxy-phenyl) -1H-tetrazole compound represented by the following formula with hexamethylenetetramine in a sulfonic acid solvent, followed by hydrolysis:
- a 1 represents an alkoxyl group
- a 2 represents a hydrogen atom, an alkyl group, or an alkyl group substituted with fluorine.
- a 1 represents an alkoxyl group
- a 2 represents a hydrogen atom, an alkyl group, or an alkyl group substituted with fluorine.
- a 1 represents an alkoxyl group
- a 2 represents a hydrogen atom, an alkyl group, or an alkyl group substituted with fluorine.
- a 1 represents an alkoxyl group
- a 2 represents a hydrogen atom, an alkyl group, or an alkyl group substituted with fluorine.
- Alkyl moiety of the alkoxyl group in A 1 may be either linear or branched. In the case of a branched chain, the branch position and the number of branches are not particularly limited. From the viewpoint that the reaction proceeds easily, those having 1 to 10 carbon atoms are preferable, and those having 1 to 4 carbon atoms are more preferable.
- Preferable examples of the alkoxyl group include a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, a butoxy group, a but-12-oxy group, a 2-methylpropoxy-1-oxy group, and a 2-methylpropoxy-2-oxy group. And the like.
- Alkyl group in A 2 may be either linear or branched.
- the branch position and the number of branches are not particularly limited. Further, from the viewpoint that the reaction proceeds easily, those having 1 to 10 carbon atoms are preferable, and those having 1 to 3 carbon atoms are more preferable.
- Preferred specific examples include a methyl group, an ethyl group, an n-propyl group, an isopropyl group and the like.
- Alkyl group wherein a hydrogen in A 2 is substituted with fluorine the availability of raw materials easiness, alkyl groups wherein all hydrogens in carbon number 1-4 linear is substituted by fluorine are preferred, carbon atoms Is more preferably an alkyl group in which 1 to 2 are substituted for all hydrogens by fluorine.
- Preferred specific examples include a trifluoromethyl group and a pentafluoroethyl group.
- a 1 is particularly preferably a methoxy group.
- the A 2, water atom, a methyl group, is Echiru group or triflate Ruo Russia methyl group particularly preferred.
- the 1- (alkoxy-phenyl) -1H-tetrazole compound represented by the above general formula (1) includes 1- (2-alkoxy-phenyl) represented by the above general formula (3) One 1H-tetrazole compound, 1- (3-alkoxy-phenyl) represented by the above general formula (5) One 1H-tetrazole compound, 1- (4-alkoxy-one) represented by the above general formula (7) Phenyl) 1H-tetrazole compound and the like.
- the 1- (2-alkoxy-phenyl) -1H-tetrazole compound of the above general formula (3) may be produced by any method. Specific examples include 1- (2-methoxy-phenyl) -1H-tetrazole, 1- (2-ethoxy-phenyl) -1H-tetrazole, 1- (2_propoxy-phenyl) -1H-tetrazol, 1 1- (2-isopropoxy-phenyl) 1H-tetrazole, 1- (2-butoxy-phenyl) 1H-tetrazole, 1- [2- (but-2-oxy) 1-phenyl] —1H-tetrazole, 1 — [2 -— (2-Methylprop-1-oxy) —phenyl] 1H-tetrazole, 1- [2- (2-methylprop-1-21x) 1-phenyl] 1-1H-tetrazole, 1- (2-methoxy) —Phenyl) 1-5-methyl-1H-tetrazole, 1- (2
- the 1- (3-alkoxy-phenyl) -1H-tetrazole compound of the above general formula (5) may be produced by any method.
- any method As a specific example,
- the 1- (4-alkoxy-phenyl) -1H-tetrazole compound of the above general formula (7) may be produced by any method.
- the amount of hexamethylenetetramine used is 1- (alkoxy-phenyl) 1-1H-tetrazole compound 1 of the above general formula (1). It is preferably from 1.0 to 3.0 mol, more preferably from 1.2 to 2.0 mol, per mol.
- the sulfonic acid solvent used in the present invention is not particularly limited as long as it does not contain water.
- the sulfonic acid solvent which dissolves the 1- (alkoxy-phenyl) -1H-tetrazole compound of the above general formula (1) is used. Is preferred. Specific examples include methanesulfonic acid, ethanesulfonic acid, trifluoromethanesulfonic acid, and pentafluorosulfonic acid, and these may be used as a single solvent or as a suitable mixed solvent.
- the amount of the sulfonic acid solvent to be used is preferably 1 to 15 ml, more preferably 5 to 10 ml for 1 g of the (alkoxy-phenyl) -1H-tetrazole compound of the general formula (1). Is more preferred.
- the reaction of the 11- (alkoxy-phenyl) -11H-tetrazole compound of the general formula (1) with hexamethylenetetramamine is carried out by heating in a sulfonic acid solvent.
- the reaction temperature is preferably about 50 to 150, more preferably about 80 to 100 nC , because if the reaction temperature is too low, the reaction rate becomes low, and if it is too high, by-products increase.
- the reaction time is preferably about 1 to 8 hours, more preferably about 2 to 5 hours.
- hydrolysis is performed by adding water into the system or adding a reaction solution to water.
- the amount of water used is preferably from 1 to 15 ml, more preferably from 5 to 15 ml, per g of the 1- (alkoxy-phenyl) -11H-tetrazole compound of the above general formula (1).
- the hydrolysis temperature is It is preferably about 0 to 30 ° C, more preferably about 0 to 15 ° C.
- the hydrolysis time is preferably about 15 minutes to 2 hours, more preferably about 30 minutes to 1 hour.
- the crude product is represented by the above general formula (2) by purification such as crystallization, recrystallization, and column chromatography. This yields an alkoxy-tetrazole-1-ylbenzaldehyde compound.
- the alkoxy-tetrazo-l-l-yrubenzaldehyde compound represented by the general formula (2) may be a 4-alkoxy-3-tetratazole-1 represented by the general formula (4).
- tetrazole-1-ylbenzaldehyde compounds Represented by alkoxy by the general formula (2) - In Tetorazoru 1- I Lou benzaldehyde compound, preferably present aldehyde groups in the ortho or para position relative to A 1.
- a 1- (alkoxy-phenyl) -11H-tetrazole compound is formylated, and an alkoxy-tetrazol-11-yl-benzaldehyde compound can be manufactured safely and efficiently.
- I R (KB r, cm-: 3155, 1688, 1607, 1516, 1468, 1439, 1292, 1258, 1221, 1 180, 1 153, 1088, 1 009, 901, 820, 671, 662, 640
- reaction solution was cooled to room temperature, and the reaction solution was added to water lm1 cooled in an ice bath, followed by stirring at 5 ° C for 30 minutes. Then, extraction was performed with dichloromethane (5 ml X3), and the obtained organic layer was washed with a 10% aqueous sodium hydroxide solution (10 ml XI) and water (10 ml XI), and then dehydrated with anhydrous magnesium sulfate for 1 hour.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005512482A JP4710608B2 (ja) | 2003-08-01 | 2004-07-15 | アルコキシ−テトラゾール−1−イル−ベンズアルデヒド化合物およびその製造方法 |
CA2531573A CA2531573C (en) | 2003-08-01 | 2004-07-15 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same |
US10/565,801 US7579480B2 (en) | 2003-08-01 | 2004-07-15 | Alkoxy-(tetrazol-1-yl)benzaldehyde compound and process for producing the same |
EP04747826A EP1650198A4 (en) | 2003-08-01 | 2004-07-15 | ALKOXYTETRAZOL-1-YLBENZALDEHYDE COMPOUND AND PROCESS FOR THE PRODUCTION THEREOF |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-285266 | 2003-08-01 | ||
JP2003285266 | 2003-08-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005012267A1 true WO2005012267A1 (ja) | 2005-02-10 |
Family
ID=34113874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/010437 WO2005012267A1 (ja) | 2003-08-01 | 2004-07-15 | アルコキシ-テトラゾール-1-イル-ベンズアルデヒド化合物およびその製造方法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US7579480B2 (ja) |
EP (1) | EP1650198A4 (ja) |
JP (1) | JP4710608B2 (ja) |
KR (1) | KR100785395B1 (ja) |
CN (1) | CN100402508C (ja) |
CA (1) | CA2531573C (ja) |
WO (1) | WO2005012267A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9673046B2 (en) | 2012-12-17 | 2017-06-06 | Mitsubishi Chemical Corporation | Gallium nitride substrate and manufacturing method of nitride semiconductor crystal |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006137691A (ja) * | 2004-11-11 | 2006-06-01 | Toyo Kasei Kogyo Co Ltd | 2−アルコキシ−5−テトラゾリル−ベンズアルデヒド化合物の製造方法 |
US8326408B2 (en) * | 2008-06-18 | 2012-12-04 | Green George H | Method and apparatus of neurological feedback systems to control physical objects for therapeutic and other reasons |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09505275A (ja) * | 1993-09-22 | 1997-05-27 | グラクソ、グループ、リミテッド | 3‐(5‐テトラゾリル‐ベンジル)アミノ‐ピペリジン誘導体およびタチキニンのアンタゴニスト |
JPH11502810A (ja) * | 1995-03-21 | 1999-03-09 | グラクソ、グループ、リミテッド | ニューロキニンアンタゴニストとしての3−ベンジルアミノ−2−フェニルピペリジン |
WO2002006263A1 (fr) * | 2000-07-19 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Procede de preparation d'un derive de benzofurane |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3925662B2 (ja) | 1995-01-12 | 2007-06-06 | グラクソ,グループ,リミテッド | タキキニンアンタゴニスト活性を有するピペリジン誘導体 |
MX9706944A (es) * | 1996-09-12 | 1998-08-30 | Pfizer | Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p. |
DE69941298D1 (de) * | 1998-09-29 | 2009-10-01 | Merck & Co Inc | Radiomarkierte neurokinin-1 rezeptor antagonisten |
-
2004
- 2004-07-15 US US10/565,801 patent/US7579480B2/en not_active Expired - Fee Related
- 2004-07-15 EP EP04747826A patent/EP1650198A4/en not_active Withdrawn
- 2004-07-15 KR KR1020067002250A patent/KR100785395B1/ko not_active IP Right Cessation
- 2004-07-15 CA CA2531573A patent/CA2531573C/en not_active Expired - Fee Related
- 2004-07-15 JP JP2005512482A patent/JP4710608B2/ja not_active Expired - Fee Related
- 2004-07-15 CN CNB2004800207209A patent/CN100402508C/zh not_active Expired - Fee Related
- 2004-07-15 WO PCT/JP2004/010437 patent/WO2005012267A1/ja active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH09505275A (ja) * | 1993-09-22 | 1997-05-27 | グラクソ、グループ、リミテッド | 3‐(5‐テトラゾリル‐ベンジル)アミノ‐ピペリジン誘導体およびタチキニンのアンタゴニスト |
JPH11502810A (ja) * | 1995-03-21 | 1999-03-09 | グラクソ、グループ、リミテッド | ニューロキニンアンタゴニストとしての3−ベンジルアミノ−2−フェニルピペリジン |
WO2002006263A1 (fr) * | 2000-07-19 | 2002-01-24 | Chugai Seiyaku Kabushiki Kaisha | Procede de preparation d'un derive de benzofurane |
Non-Patent Citations (1)
Title |
---|
SUZUKI Y, ET AL.: "Formylation of phenols with electron-withdrawing groups in strong acids. Synthesis of substituted salicylaldehydes", CHEMICAL & PHARMACEUTICAL BULLETIN, vol. 31, no. 5, 1983, pages 1751 - 1753, XP008028006 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9673046B2 (en) | 2012-12-17 | 2017-06-06 | Mitsubishi Chemical Corporation | Gallium nitride substrate and manufacturing method of nitride semiconductor crystal |
Also Published As
Publication number | Publication date |
---|---|
CA2531573C (en) | 2010-04-13 |
JPWO2005012267A1 (ja) | 2006-09-14 |
EP1650198A4 (en) | 2007-11-21 |
EP1650198A1 (en) | 2006-04-26 |
KR100785395B1 (ko) | 2007-12-13 |
CN100402508C (zh) | 2008-07-16 |
JP4710608B2 (ja) | 2011-06-29 |
US7579480B2 (en) | 2009-08-25 |
CA2531573A1 (en) | 2005-02-10 |
US20070060630A1 (en) | 2007-03-15 |
KR20060059994A (ko) | 2006-06-02 |
CN1826329A (zh) | 2006-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5202635B2 (ja) | インテグラーゼ阻害剤の調製のためのプロセスおよび中間体 | |
TW200821283A (en) | Process and intermediates for preparing integrase inhibitors | |
WO2005012267A1 (ja) | アルコキシ-テトラゾール-1-イル-ベンズアルデヒド化合物およびその製造方法 | |
US8455700B2 (en) | Method for producing phenylalkane-1-ols | |
JP2005518427A (ja) | 新規ボロネートエステル | |
JP4892472B2 (ja) | 5−クロロ−2,4−ジヒドロキシピリジンの製造方法 | |
JP3563643B2 (ja) | イミダゾリン化合物、その中間体、およびそれらの製造方法、並びにアゼピン化合物およびその塩の製造方法 | |
JP2001513108A (ja) | ニコチン酸の調製プロセス | |
TWI500596B (zh) | 合成3,4-二甲氧基雙環[4.2.0]辛-1,3,5-三烯-7-甲腈之方法,及於合成依伐布雷定(ivabradine)及其與醫藥上可接受酸之加成鹽之應用 | |
JP4032861B2 (ja) | β−オキソニトリル誘導体又はそのアルカリ金属塩の製法 | |
WO2004083213A1 (fr) | Derives de 4,6-dihydrofuro[3,4-d]imidazole-6-one, sels de ceux-ci ainsi que procede de preparation associe | |
WO2003014067A1 (en) | PROCESS FOR PRODUCING ß-OXONITRILE COMPOUND OR ALKALI METAL SALT THEREOF | |
JPS584698B2 (ja) | 2−(3−ベンゾイルフエニル)プロピオン酸の製造方法 | |
JP3986587B2 (ja) | ピラジンジカルボン酸誘導体及びその製造方法 | |
JP3097678B2 (ja) | アファノルフィン中間体 | |
EP2011792A1 (en) | 2-alkenyl-3-aminothiophene derivative and method for producing the same | |
WO2006051751A1 (ja) | 2-アルコキシ-5-テトラゾリル-ベンズアルデヒド化合物の製造方法 | |
WO2023013757A1 (ja) | アルキルシリルオキシ置換ベンジル化合物の製造方法 | |
JP2013503136A (ja) | ピラゾールグリコシド誘導体の製造方法 | |
JP2010083798A (ja) | ω−ヒドロキシ長鎖脂肪酸誘導体の製造方法 | |
WO2011065351A1 (ja) | シクロヘキサン誘導体の製造方法 | |
WO2006068102A1 (ja) | 2-(ピラゾール-1-イル)ピリジン誘導体 | |
CN1290247A (zh) | 制备抗叶酸剂的方法和中间体 | |
WO2003014051A1 (en) | Process for preparation of 2-phenylacetophenone derivatives and precursors therefor | |
JP2002114765A (ja) | 3−アミノ−4−カルボニルピラゾール化合物の製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480020720.9 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004747826 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 6102/DELNP/2005 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2531573 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007060630 Country of ref document: US Ref document number: 10565801 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005512482 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067002250 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004747826 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067002250 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10565801 Country of ref document: US |